PDIA2 is associated with the prognosis of prostate cancer, and downregulation of PDIA2 delays the progression of prostate cancer cells

Sep 21, 2026

Uploaded by Miles

Protein disulfide-isomerase A2 (PDIA2) is identified as a gene whose aberrant expression links to tumor biology and patient outcomes. Elevated PDIA2 correlates with poor prognosis in prostate cancer, including worse progression-free survival, higher Gleason scores, advanced tumor stage, lymph node metastasis, and increased PSA. PDIA2 is implicated in promoting prostate cancer growth, invasion, metastasis, and reduced dasatinib response. Using TCGA-based bioinformatics and clinical data, the study builds a progression-free survival prediction model and further validates PDIA2 roles through vitro and in vivo experiments.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Background and Rationale

PDIA2 expression and clinical prognosis in prostate cancer

Links to androgen receptor signaling and standard therapies

PDIA2 Biological Role

Effects on apoptosis, proliferation, differentiation, and immune response

Mechanistic implication for invasion and microvascularization

Study Design and Methods

TCGA screening and multi-database bioinformatics analysis

Clinical validation and prognostic modeling

Experimental confirmation (in vitro and in vivo)

Results and Conclusions

PDIA2 as a biomarker and therapeutic target

[www. nature.com/scientificreports](www. nature.com/scientificreports) OPEN PDIA2 is associated with the prognosis of prostate cancer, and downregulation of PDIA2 delays the progression of prostate cancer cells Qiang Zhou1, Yue Ge2, Sheng Ma2, Zezhong Xiong2, Yanan Wang2, Le Li2, Ling Li1, Zheng Chao2, Junbiao Zhang2, Tengfei Li2, Zixi Wu2, Yuan Gao2, Guanyu Qu2, Haoxiao Dong2, Zhihua Wang2􀀍, Wang Jing2􀀍 & Guojun Chen1􀀍 Protein Disulfide-IsomeraseA2 (PDIA2) is a gene that encodes proteins, responsible for protein folding and modification within cells. The development and course of many disorders are intimately linked to the aberrant expression of PDIA2. Nevertheless, more research is necessary to fully understand PDIA2’s biological significance in pan-cancer, notably in prostate cancer (PCa) . PDIA2 expression is elevated in various tumors and closely related to patient prognosis. Patients with prostate cancer who express PDIA2 high in particular have a bad prognosis in terms of progression-free survival. In addition, the upregulation of PDIA2 expression in prostate cancer patients is accompanied by higher Gleason scores, advanced tumor staging, lymph node metastasis, and elevated PSA levels. Detailed experiments further demonstrate that PDIA2 is a carcinogenic gene affecting prostate cancer cells’response to dasatinib therapy. For patients with prostate cancer, there is a clear positive connection between the expression level of PDIA2 and a bad prognosis. The prostate cancer treatment efficacy of dasatinib is hampered by PDIA2, which is intimately linked to the growth, invasion, and metastasis of PCa cells. In summary, our research highlights the potential of PDIA2 as a biomarker for the diagnosis and management of PCa. Keywords PDIA2, Prostate cancer, Prognosis, Dasatinib One of the most prevalent malignant tumors in males, prostate cancer (PCa) primarily affects the prostate’s epithelial tissue and has a variable incidence rate across different nations and areas1. Based on data from the World Health Organization (WHO), prostate cancer is becoming more commonplace worldwide and is now the second most common cause of death for male malignant tumors2. Advancements have been made in the early diagnosis and treatment of prostate cancer in recent years thanks to the promotion of early screening, the use of novel endocrine therapy medications, and robotics-assisted minimally invasive surgery3. Prostate cancer occurs and develops mostly because of the androgen receptor. For advanced prostate cancer, androgen deprivation therapy (ADT) is the primary treatment4. PDIA2 is a gene that encodes proteins, commonly known as “Protein Disulfide Isomerase A2”. PDIA2 codes for a significant endoplasmic reticulum protein involved in intracellular protein stability maintenance and accelerating intracellular protein folding and assembly5. PDIA2 plays a significant role in diverse biological processes, involving cell apoptosis, cell multiplication, cell differentiation, immune response, etc. PDIA2 expression is significantly upregulated in tumor cells, which is strongly linked to metastasis, aggressiveness, and tumor cell proliferation6. It has been suggested that the increased expression of PDIA2 can promote tumor invasion, and the main mechanism is that PDIA2 mobilizes tissue factors to regulate migrating human vascular smooth muscle cells and promote tumor microvascularization7. Therefore, PDIA2 is considered a potential therapeutic target and has significant implications for the treatment of related diseases. PCa incidence and 1Department of Urology, Qinghai University Affiliated Hospital, Qinghai University Medical College, Xining, China. 2Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 􀀍 [email: zhwang_hust@hotmail.com](email: zhwang_hust@hotmail.com); [383213263@126.com](383213263@126.com); [chenguojun68@126.com](chenguojun68@126.com) [www. na

FAQs

How does PDIA2 expression relate to prostate cancer prognosis?

Higher PDIA2 expression in prostate cancer is associated with poor prognosis, including worse progression-free survival and more aggressive clinicopathologic features such as higher Gleason scores and advanced staging.

What is the relationship between PDIA2 and dasatinib therapy?

PDIA2 is described as a carcinogenic factor that affects prostate cancer cells’ response to dasatinib, and dasatinib efficacy is hampered in the context of PDIA2 involvement.

What approach was used to study PDIA2 in prostate cancer?

The study screened biomarkers using TCGA and conducted comprehensive bioinformatics exploration across multiple databases, then focused on clinical characteristics and prognostic analysis using TCGA data and additional clinical cohorts.

Sep 21, 2026

Uploaded by Miles